SK chemicals launches <Laton>, a Melatonin-based treatment for insomnia.
SK chemicals (CEO: Kwang Hyun Jeon) announced on the 26th that SK will launch <Laton PR Tab.>, a drug indicated for the treatment of insomnia characterized by poor sleep quality on the 19th.
Laton, a drug for the treatment of insomnia released by SK chemicals, improves the sleep quality of patients by maintaining an appropriate melatonin concentration over 8-10 hours, which is similar to the normal secretion of melatonin in the body. Since melatonin is a naturally produced hormone, users will avoid experiencing the side effects of conventional sleeping pills, such as showing less dependence and tolerance.
SK chemicals Leader Hanjo Jung emphasized, “As Korea reached the fastest aging rate among OECD countries, the number of middle-aged patients complaining of insomnia due to a decrease in melatonin is increasing. The localization of this melatonin-based insomnia treatment reflects our efforts to improve the quality of life and reduce the financial burden of patients.”
SK chemicals’ <Laton> is orally administered 1 tablet once daily, 1 to 2 hours before bedtime after a meal and should be swallowed whole without chewing or crushing. According to the Health Insurance Review and Assessment Service in Korea, the number of insomnia patients reached approximately 660,000 in 2019, and the patient number has been increasing by about 6% annually for the past 3 years.
[Photo] SK chemicals Insomnia Drug